MBRC 301
Alternative Names: MBRC-301Latest Information Update: 17 May 2024
At a glance
- Originator MBrace Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 30 Apr 2024 Early research in Cancer in USA (Parenteral) prior to April 2024 (MBrace Therapeutics pipeline, April 2024)